Nxera Pharma Co., Ltd. (TSE Prime: 4565; "Nxera Pharma") is a Japanese biopharmaceutical company that aims to expand globally by combining drug discovery and early development capabilities and a unique, proprietary platform technology based in the UK with late-stage clinical development and commercialization functions in Japan and the APAC region (excluding China). The company generates revenue mainly through alliances with major global pharmaceutical companies and sales of its own products.